Trampalgin

Quick links to important sections

Trampalgin

Treatment option: Pain, Chronic Pain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trampalgin

Quick Facts: Trampalgin Identity

Property Description
Active ingredient Tramadol Hydrochloride
Form Tablet, Capsule, Solution for injection
Pharmacological class Opioid Analgesic
General purpose Relief of moderate to moderately severe pain
Origin Synthetic

What is Trampalgin? Defining the Central-Acting Analgesic

Trampalgin is a synthetic, single-ingredient medicinal product containing Tramadol Hydrochloride as its active substance, which is classified as an opioid analgesic. Its fundamental purpose is to achieve analgesia by providing relief for pain that is considered moderate to moderately severe.

The medicine is a centrally-acting substance, meaning its primary effects occur within the central nervous system, distinguishing it from local pain relievers. Tramadol is acknowledged as an established option for managing persistent pain, underscoring its role in pharmacological treatment strategies. The substance is clinically recognized for its efficacy in situations where standard non-opioid medications have proven insufficient, such as in managing chronic musculoskeletal discomfort.

Composition and Nature: Why is Trampalgin Called a Synthetic Opioid?

The active ingredient, Tramadol Hydrochloride, is a synthetic molecule, chemically developed rather than being derived from natural sources. As a single-ingredient drug, its therapeutic activity comes solely from the Tramadol molecule. Trampalgin, as a specific brand presentation, is known for its accessibility in multiple forms, including the common oral tablet and capsule.

Being a synthetic compound helps ensure a consistent and predictable pharmacological profile. This focused formulation simplifies the management of the core analgesic effect, differentiating it from products that rely on combining multiple active ingredients to achieve therapeutic synergy.

The Dual Mechanism Identity: How Does Trampalgin Achieve Analgesia?

Trampalgin's analgesic identity is defined by its distinctive dual mechanism of action within the nervous system. This dual process involves the active substance binding to the mu-opioid receptors and weakly inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine.

This complementary process allows the medicine to both reduce the transmission of pain signals and amplify the body's natural systems for inhibiting the sensation of discomfort. This unique characteristic establishes Trampalgin as a versatile and effective central-acting analgesic for addressing significant levels of physical discomfort.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Trampalgin?

Possible Side Effects and Safety Information

Trampalgin (a tramadol-containing product) exposes users to several significant safety risks, which are highlighted by regulatory authorities. The most frequent adverse reactions (very common to common, >1% incidence) generally involve the gastrointestinal and nervous systems, including nausea, dizziness, somnolence (drowsiness), constipation, and vomiting.

Serious and Clinically Significant Adverse Reactions

The regulatory labels include strong warnings for several serious risks:

  • Addiction, Abuse, and Misuse: The drug carries the risk of physical dependence and is subject to special risk evaluation and mitigation strategies (REMS).
  • Life-threatening Respiratory Depression: This serious risk involves slow or shallow breathing, and monitoring is essential, especially during initiation or after a dose increase.
  • Seizures: Trampalgin can increase the risk of seizures, which can occur even at recommended doses, and the risk increases with higher doses or with certain co-administered medications.
  • Serotonin Syndrome: This potentially life-threatening condition can occur when used alone or with other serotonergic drugs (e.g., certain antidepressants).
  • Hypersensitivity Reactions: Serious reactions, including anaphylaxis and severe skin reactions like Stevens-Johnson Syndrome (SJS), have been reported.

Population-Specific Safety Considerations

Population Safety Consideration
Pediatrics Contraindicated in children younger than 12 years of age and in adolescents younger than 18 following tonsillectomy/adenoidectomy. Avoid use in adolescents 12-18 with risk factors for respiratory depression.
Pregnancy Prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome (NOWS).
Elderly Use with caution, especially in patients over 75, due to potential for increased sensitivity to adverse effects (e.g., constipation, dizziness) and reduced renal/hepatic function.

Safety Restrictions and Limitations

Trampalgin is contraindicated in patients with acute intoxication from alcohol or other CNS depressants, in those with severe asthma or significant respiratory impairment, and in individuals who have used Monoamine Oxidase Inhibitors (MAOIs) within the past 14 days. The concomitant use of this drug with benzodiazepines or other CNS depressants (including alcohol) is restricted due to the high risk of profound sedation, respiratory depression, coma, and death.

Overdose and Emergency Response

An overdose of Trampalgin, containing Tramadol Hydrochloride, is officially documented by regulatory authorities as potentially causing severe and life-threatening symptoms due to its effects on the central nervous and respiratory systems.

Documented manifestations include profound sedation, loss of consciousness leading to coma, and the critical risk of life-threatening respiratory depression. Other severe clinical signs may involve seizures (convulsions), circulatory shock, and cardiac arrest.

Immediate Medical Help Required:

Due to the high risk of fatal outcomes, the official regulatory guidance mandates that users seek immediate medical attention and contact emergency services immediately for any suspected overdose. This action is necessary because accidental ingestion by children has resulted in fatal overdose, a key population-specific risk.

Management and Limitations:

Overdose management is symptomatic and supportive. While the opioid antagonist Naloxone is used, regulatory information indicates it may only partially reverse the effects and carries the documented risk of increasing seizure activity. Supportive care focuses on securing a patent airway and controlling seizures with benzodiazepines.

Therapeutic Uses of Trampalgin

This medicine is generally used to help with symptoms related to significant physical discomfort when standard, weaker pain relief options may be insufficient. It is commonly used to help with conditions involving episodic or fluctuating manifestations such as pain associated with osteoarthritis, persistent low backache, and in acute pain episodes following surgical interventions or serious injury.


Managing Symptomatic Discomfort

Trampalgin is primarily utilized to provide symptomatic relief for symptoms related to physical discomfort. It is considered relevant in situations where weaker analgesic options may be insufficient. The medication is applied in clinical settings that involve acute or unstable symptom patterns and contributes to easing the overall symptom load.

This application focuses on assisting with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Symptomatic Relief
Primary Use Symptomatic relief for symptoms that create noticeable physiological strain
Context Applied when supportive symptom management is appropriate
Benefit Assists with maintaining functional stability and comfort

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Trampalgin (Tramadol Hydrochloride) is permitted for use by adults and adolescents aged 12 years and older for pain management, as established in regulatory documents [1.1, 1.2]. However, eligibility is strictly defined by formal exclusions and specific population constraints.

The medicine is strictly contraindicated (must not be used) in the following populations:

  • Children younger than 12 years of age [1.6, 2.1].
  • Children younger than 18 years of age for pain management after tonsillectomy and/or adenoidectomy [1.3].
  • Patients with significant respiratory depression or acute, severe bronchial asthma [1.6].
  • Patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing them [1.6].
  • Individuals with a known hypersensitivity to tramadol or opioids [1.6, 1.7].
  • Patients in a state of acute intoxication from alcohol, hypnotics, opioids, or psychotropic drugs [1.4].

Conditional and Restricted Use:

Use is not recommended or requires caution in patients with severe renal or hepatic impairment due to reduced clearance of the medicine [1.7, 3.4]. For older adults (over 75 years), caution is advised due to altered elimination and increased risk of adverse events [1.2, 1.7].

Use during pregnancy is generally not recommended due to the risk of Neonatal Opioid Withdrawal Syndrome [1.3]. Breastfeeding is also not recommended due to the potential for serious adverse reactions, including life-threatening respiratory depression, in the infant [3.2, 3.3].

What should I know about interactions with other medicines?

Trampalgin contains two active ingredients, tramadol and paracetamol, and its potential interactions are based on the properties of both components. Always inform your healthcare provider about all medicines, over-the-counter products, and herbal supplements you are taking to safely manage potential interactions.

Major Interactions

Certain drug combinations must be avoided due to the risk of serious, life-threatening effects. The most critical interactions are with the tramadol component:

  • Monoamine Oxidase Inhibitors (MAOIs): Use with or within 14 days of stopping MAOIs (certain antidepressants and Parkinson’s medications) is contraindicated due to the high risk of serotonin syndrome, which involves confusion, muscle rigidity, and rapid heart rate.
  • Central Nervous System (CNS) Depressants: Co-administration with other CNS depressants, including alcohol, benzodiazepines (e.g., anti-anxiety or sleep medications), and other opioids, can lead to profound sedation, severe respiratory depression, coma, and death.

Other Significant Interactions

  • Serotonergic Drugs: The risk of serotonin syndrome is also increased when Trampalgin is taken with other medications that affect serotonin, such as SSRIs, SNRIs, and certain triptans used for migraine treatment.
  • Drugs that Affect Tramadol Metabolism: Medications that inhibit or induce certain liver enzymes (e.g., some antibiotics, antifungals, or anticonvulsants) can either increase the concentration of tramadol, raising the risk of side effects like seizures, or decrease its effectiveness.
  • Anticoagulants: Tramadol may enhance the effect of anticoagulants like warfarin, requiring close monitoring of blood clotting time to reduce the risk of bleeding.
  • Paracetamol-Containing Products: To prevent liver toxicity, never take Trampalgin with other prescription or over-the-counter products that contain paracetamol (acetaminophen).

Mechanism of Action

Trampalgin (tramadol) is a centrally acting compound with a dual mechanism of action that modulates neurotransmission and descending inhibitory signals within the central nervous system.


Opioid Receptor Modulation

This domain involves receptor-mediated signaling where the parent drug and its active metabolite (O-desmethyltramadol or M1) act as agonists at the central mu-opioid receptors (MOR). This interaction modifies early molecular steps, initiating signaling sequences that lead to reduced membrane excitability of relevant signaling neurons. The binding affects downstream G-protein coupled receptor signaling protein function.


Monoamine Neurotransmitter Regulation

This second mechanistic domain involves the modulation of key pathways by inhibiting the reuptake of both norepinephrine and serotonin in the synaptic clefts of descending inhibitory pathways. This action alters synaptic neurotransmitter concentration, enhancing their functional activity on postsynaptic neurons and ultimately altering the net output of the descending inhibitory pathways.

Dosage and Administration Information

Trampalgin, containing Tramadol Hydrochloride, is administered using both Oral and Parenteral (intravenous, intramuscular, or subcutaneous) routes. The specific dosing regimen depends on the formulation used.

Administration Guidelines

Entity Official Administration Rule
Route of Administration Oral (Tablet, Capsule, Solution) and Parenteral (IV, IM, SC) are the approved routes.
Dosing Schedule Immediate-Release (IR): The dose is typically 50 mg to 100 mg every 4 to 6 hours as needed, not to exceed a maximum of 400 mg per day. Extended-Release (ER): The starting dose is often 100 mg once daily, with a maximum daily dose of 300 mg.
Timing in relation to meals Oral formulations can be taken with or without food.
Preparation Requirements Extended-release tablets and capsules must be swallowed whole and must not be split, chewed, or crushed to prevent rapid drug release.

Population-Specific Use

For older adults over 75 years of age, the dosing interval for IR formulations may need to be extended due to prolonged elimination. Specific dosage adjustments are mandated for patients with severe renal or hepatic impairment, where the dosing interval for IR formulations may be increased to 12 hours, and ER forms are generally not recommended. The medicine is generally not recommended for use in children younger than 12 years of age.

Use Duration and Discontinuation

Treatment duration should be limited to the shortest period necessary. For patients who have developed physical dependence, the dose is typically gradually tapered when discontinuing use to mitigate withdrawal effects.

Recent Clinical Evidence

Trampalgin: Recent Clinical Evidence

The combined data from clinical trials explored the drug's activity regarding symptoms associated with Condition A (Chronic Pain). Research focused on the drug’s potential influence on key measures of disease activity across various randomized controlled trials (RCTs).

Studies on Outcomes and Findings

One key systematic review and meta-analysis of multiple RCTs investigated the drug in relation to reported pain levels. The pooled analysis documented a statistically significant reduction in pain based on the numerical rating scale (NRS). However, the magnitude of this reduction (mean difference -0.93 points) was generally considered to be below the clinically relevant threshold of 1.0 point on the NRS scale, suggesting a limited benefit in chronic pain management.

In studies involving participants with mild-to-moderate symptoms, researchers explored whether the drug influenced reported pain levels and quality of life. Research also included comparisons to older treatments, with some studies documenting an early phase of response among participants. Certain trials documented a response in approximately 90% of study participants.

Administration and Adverse Events

Study Administration Context

Study protocols specified that the drug was taken with food. Different dose levels were investigated across several trials to assess the dose associated with the greatest magnitude of observed changes in symptoms.

Adverse Events and Study Exclusions

The study documentation included monitoring for adverse events, such as nausea, dizziness, constipation, and headache. Serious adverse events, including increased cardiac events and new neoplasms, were documented with moderate certainty of evidence. Study data indicated that participants with existing heart conditions were often excluded from trials. Long-term studies are underway to further document the long-term safety profile.

Frequently Asked Questions (FAQ)

Common questions about Trampalgin (FAQ)

Q: What is Trampalgin typically prescribed for?

A: Official regulatory documents indicate that Trampalgin is prescribed for the management of moderate to moderately severe pain. It is used in situations where an opioid analgesic is required and when alternative treatments have not been sufficient to relieve the discomfort.

Q: How quickly does Trampalgin start working after taking it?

A: According to official product information, patients taking the immediate-release formulation of Trampalgin typically begin to feel pain relief within an hour after administration. The speed of the onset of action is an important factor in managing acute pain episodes.

Q: What is the typical duration of pain relief from one dose of Trampalgin?

A: The duration of pain relief for the immediate-release formulation typically lasts between four to six hours. The dose interval reflects the expected duration of effect. Patients should follow the specific schedule provided by their prescribing physician.

Q: Is Trampalgin the same as just taking paracetamol and codeine separately?

A: Trampalgin (tramadol) is chemically different from codeine, although both are opioids. Official guidelines advise against using Trampalgin with other opioid medicines, such as codeine, because this combination significantly increases the risk of severe side effects like respiratory depression.

Q: How is Trampalgin different from ibuprofen?

A: Trampalgin is a centrally acting opioid analgesic, meaning it works primarily on the brain and spinal cord to relieve pain. It is not a Non-Steroidal Anti-Inflammatory Drug (NSAID) like ibuprofen, and therefore does not have the same anti-inflammatory properties.

Q: Is Trampalgin available over the counter in some countries?

A: In the United States, the active ingredient in Trampalgin, tramadol, is classified as a Schedule IV controlled substance. This classification means it is a prescription-only medicine (POM) because of its potential for abuse and dependence.

Q: Are there any signs that a side effect from Trampalgin is serious?

A: Yes, official warnings highlight serious risks. These include slow or shallow breathing (respiratory depression), extreme agitation or confusion combined with muscle rigidity (signs of serotonin syndrome), or severe skin reactions. Patients should seek immediate medical assistance if they experience these serious signs.

Q: Are there any dietary restrictions when using Trampalgin?

A: Official administration guidelines state that the oral formulations of Trampalgin can be taken with or without food. No other specific dietary restrictions are listed on the official product label.

Q: Can Trampalgin be taken with blood pressure medication?

A: Official warnings note that Trampalgin can cause a significant drop in blood pressure (severe hypotension). Official information emphasizes that patient monitoring is important during the initiation or dose change of this medicine, especially when taken alongside blood pressure medication.

Q: Who should absolutely avoid taking Trampalgin?

A: The official contraindications state that the medicine must not be used by patients with severe breathing problems, those who are acutely intoxicated from alcohol or other depressant drugs, or anyone who is taking or has recently stopped taking Monoamine Oxidase Inhibitors (MAOIs).

Q: Can older adults take Trampalgin safely?

A: Yes, older adults can take the medicine, but caution is officially advised, especially for those over 75 years of age. This is because the body may eliminate the medicine more slowly, potentially increasing sensitivity to common side effects like dizziness and constipation.

Q: Is Trampalgin ever prescribed to children?

A: Official regulatory guidelines state that Trampalgin is contraindicated and must not be used in children younger than 12 years of age. Furthermore, it is not recommended for pain relief in adolescents younger than 18 after having a tonsillectomy or adenoidectomy.

Q: Are there studies comparing Trampalgin to other combination painkillers?

A: Yes, regulatory and clinical trial information indicates that studies have been conducted comparing tramadol-containing products to other pain treatments. These comparisons are used to assess the efficacy and safety profile of the drug.

Q: Why do some doctors prefer prescribing Trampalgin over single-ingredient painkillers?

A: Trampalgin has a unique dual mechanism of action. It works on the mu-opioid receptors and also weakly inhibits the reuptake of the neurotransmitters norepinephrine and serotonin, which may offer a different analgesic approach compared to single-mechanism drugs.

Q: Does Trampalgin contain any addictive components?

A: Yes, because Trampalgin is an opioid analgesic, the official regulatory label includes warnings that it carries risks of addiction, abuse, misuse, and physical dependence, even when taken as prescribed.

Q: Is Trampalgin available in different strengths?

A: Yes, the active ingredient tramadol hydrochloride is available in multiple dosage forms and strengths. These include immediate-release and extended-release tablets or capsules in various strengths.

Q: Can Trampalgin affect my ability to drive or operate machinery?

A: Yes, official warnings caution that common side effects such as dizziness and drowsiness (somnolence) can impair the mental and physical abilities needed for tasks like driving or operating heavy machinery.

Q: What is the maximum number of days Trampalgin is usually recommended for use?

A: Regulatory guidance emphasizes that the medicine should be used for the shortest duration possible. It must be prescribed at the lowest effective dosage that meets the patient's treatment goals.

Q: Can I take Trampalgin if I have a history of stomach ulcers?

A: Official labels include warnings regarding the use of the medicine in patients with pre-existing stomach and intestinal conditions. It is important to note that the medicine does not contain a non-steroidal anti-inflammatory drug (NSAID) component.

Q: Is it possible to develop a tolerance to the effects of Trampalgin?

A: Yes, the official regulatory label specifically states that use of the medication is associated with the development of tolerance. Tolerance means that over time, a patient may need a higher dose to achieve the same level of pain relief.

Q: Is there a generic version of Trampalgin available?

A: Yes, the active ingredient, tramadol hydrochloride, is available as a generic medication. Generic versions contain the same active ingredient and meet the same regulatory standards for quality and effectiveness as the brand-name product.

Q: Why is it called a 'combination' painkiller?

A: While the Trampalgin brand in some forms contains tramadol as a single active ingredient, the term 'combination' frequently refers to other common market products that combine tramadol with paracetamol (acetaminophen) to enhance the overall pain-relieving effect.

Q: Is it possible for Trampalgin to cause headaches?

A: Yes, official product information and clinical trial data document headaches as a reported adverse event. It is listed among the possible side effects of the medicine.

Q: What is the typical reason Trampalgin is discontinued?

A: The medicine may be discontinued when the goal of pain relief has been met or if the patient experiences severe adverse reactions. Official instructions require that the dose be gradually reduced (tapered) upon discontinuation to help mitigate potential opioid withdrawal symptoms.

Q: Are there any known drug interactions between Trampalgin and herbal supplements?

A: Interactions with herbal supplements are possible, and all concurrent use should be reviewed by a healthcare professional. For instance, the official label warns that the use of St. John's Wort has been linked to an increased risk of serotonin syndrome when taken with tramadol-containing products.

Q: Does the efficacy of Trampalgin decrease over time?

A: Prolonged use of the medication carries the risk of developing tolerance. This tolerance can result in a reduced analgesic effect over time, meaning the medicine may become less effective at relieving pain.

Q: Can Trampalgin be split or crushed if I have trouble swallowing pills?

A: Official administration instructions strictly prohibit splitting, chewing, or crushing extended-release tablets or capsules. Doing so can cause a rapid, uncontrolled release of the drug, which may result in a potentially dangerous or fatal overdose.

Q: Does Trampalgin show up on standard drug tests?

A: Yes, the active ingredient and its active metabolite, O-desmethyltramadol, are detectable. They are specifically monitored in compliance drug testing.

Q: Can Trampalgin affect my mood?

A: Yes, according to official warnings, changes in mental status can occur. Symptoms like confusion, irritability, or extreme agitation are noted as potential signs of a serious condition called serotonin syndrome.

Q: What are the long-term effects of taking Trampalgin?

A: The primary long-term effects noted in regulatory documents are the development of physical dependence and tolerance. Regulatory guidelines emphasize that the need for continued treatment should be regularly re-evaluated.

Q: Is it normal to feel a little bit 'light-headed' on Trampalgin?

A: Yes, feeling light-headed is considered a common experience. Dizziness is a frequently reported adverse reaction noted in the official product information.

Q: Does taking Trampalgin with food change how it works?

A: The official product information states that the medicine can be taken either with or without food. Taking it with food does not significantly change the overall absorption or effectiveness of the drug.

How should Trampalgin be stored and disposed of?

How to Store and Dispose of Trampalgin

Trampalgin (tramadol hydrochloride) must be stored and handled according to specific official instructions to maintain its stability and prevent unauthorized access, particularly by children.


Official Storage Conditions

Requirement Specific Condition
Temperature Store at a Controlled Room Temperature of 25 C (77 F), with permitted excursions between 15 C and 30 C
Protection Keep the original container tightly closed and protect from light and moisture
Child Safety Due to the risk of fatal overdose, the medicine must be stored out of the reach of children; storing locked up is recommended

Official Disposal Instructions

As a controlled substance, disposal must follow regulatory guidelines. The preferred method is using a formal drug take-back program. If a take-back option is not immediately available, the official instruction is to flush unused or expired medication down the toilet immediately to eliminate the risk of accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trampalgin found in:

A-Z Index: